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NCoA6 (also referred to as NRC, ASC-2,TRBP, PRIP and RAP250) was originally isolated as a ligand-dependent
nuclear receptor interacting protein. However, NCoA6 is a multifunctional coregulator or coactivator necessary
for transcriptional activation of a wide spectrum of target genes.The NCoA6 gene is amplified and
overexpressed in breast, colon and lung cancers. NCoA6 is a 250 kDa protein which harbors a potent N-terminal
activation domain, AD1; and a second, centrally-located activation domain, AD2, which is necessary for
nuclear receptor signaling.The intrinsic activation potential of NCoA6 is regulated by its C-terminal STL
regulatory domain. Near AD2 is an LxxLL-1 motif which interacts with a wide spectrum of ligand-bound NRs
with high-affinity. A second LxxLL motif (LxxLL-2) located towards the C-terminal region is more restricted
in its NR specificity.The potential role of NCoA6 as a co-integrator is suggested by its ability to enhance
transcriptional activation of a wide variety of transcription factors and from its in vivo association with a
number of known cofactors including CBP/p300. NCoA6 has been shown to associate with at least three
distinct coactivator complexes containing Set methyltransferases as core polypeptides.The composition of
these complexes suggests that NCoA6 may play a fundamental role in transcriptional activation by modulating
chromatin structure through histone methylation. Knockout studies in mice suggest that NCoA6 is an essential
coactivator. NCoA6
-/- embryos die between 8.5-12.5 dpc from general growth retardation coupled with
developmental defects in the heart, liver, brain and placenta. NCoA6
-/- MEFs grow at a reduced rate compared
to WT MEFs and spontaneously undergo apoptosis, indicating the importance of NCoA6 as a prosurvival and
anti-apoptotic gene. Studies with NCoA6
+/- and conditional knockout mice suggest that NCoA6 is a pleiotropic
coregulator involved in growth, development, wound healing and maintenance of energy homeostasis.
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In metazoans, more than 70 different nuclear hormone
receptors (NRs) have been identified
(http://www.nursa.org), which comprise a superfamily. All
NRs share a common modular structure comprised of an
N-terminal variable "A/B" domain, a central zinc-finger
containing DNA binding "C" domain (DBD), a "hinge
region" referred to as the "D" region and a C-terminal
"EF" domain.The C-terminal EF region (and for some
receptors DEF) binds ligand and comprises the ligand
binding domain (LBD), which harbors a ligand-dependent
activation function referred to as AF2 [Aranda and
Pascual, 2001]. A variety of small molecules such as
endocrine hormones, fatty acids, cholesterol derivatives
and products of lipid metabolism act as ligands for various
NRs. In general, NRs are involved in growth and
development, maintenance of cellular homeostasis,
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resistance [Anghel and Wahli, 2007; Evans et al., 2004].
The mechanism that underlies these processes involves
transcriptional activation or repression of NR target genes.
Thus, NRs function as binary switches. In the apoform
or unliganded state, some of the NRs repress
transcription, while in the liganded state, NRs act as
transcriptional activators. NR-mediated activation and
repression has been the focus of research for the last
two decades. However, the identification of NRs as
sensors of cellular metabolism led to a renewed interest
in identification and cloning of corepressors and
coactivators for NRs.
The research regarding the mechanism of transcriptional
activation by NRs evolved in the early 1990s from a
simple model that depicted the association of NRs with
ligands and basal factors of the transcription apparatus
[Aranda and Pascual, 2001].The current model on the
mechanism of NR-mediated activation takes into account
the complex macromolecular network of inter- and
intramolecular interactions of chromatin remodeling
factors, Mediator components and coactivator complexes.
These macromolecular complexes, in concert with NRs,
the basal transcription complex and RNA polymerase
cause productive transcription of NR-regulated target
genes.The discovery of coactivators was the result of a
cumulative endeavor. A number of laboratories
contributed to identification, cloning and characterization
of various NR coactivators. Initial impetus in the
identification of coactivators was provided by the
discovery of 140 kDa and 160 kDa proteins known as
ER-associated proteins (ERAPs) [Halachmi et al., 1994]
and receptor-interacting proteins (RIPs) [Cavailles et al.,
1994].Thus, it became clear that the process of NR
activation is orchestrated by regulators of transcription
now popularly known as coactivators. In 1995, the first
member of the p160 family of coactivators was cloned
and identified as SRC-1 [Onate et al., 1995]. It was soon
followed by cloning of TIF-2/GRIP-1 (SRC-2) [Hong et
al., 1996;Voegel et al., 1996] and pCIP, ACTR, RAC-3,
TRAM-1, AIB1 (SRC-3) by various groups [Anzick et al.,
1997; Chen et al., 1997; Li et al., 1997;Takeshita et al.,
1997;Torchia et al., 1997].
The hunt for novel coactivators for NRs continued using
both yeast two-hybrid screening and biochemical
purification of protein complexes associated with liganded
NRs.Two similar, if not identical, multiprotein coactivator
complexes referred to as TRAPs (thyroid hormone
receptor interacting proteins) [Fondell et al., 1996] and
DRIPs (vitamin D receptor interacting proteins) [Rachez
et al., 1999] were isolated from HeLa cells using in vivo
(TRAPs) and in vitro (DRIPs) biochemical approaches.
The TRAP/DRIP complex is one of several related
complexes which share components and are thought to
modulate the activities of a variety of transcription factors
including the NRs, Sp1, NF-kB (p65), VP16, E1A and
p53 [Boyer et al., 1999; Ito and Roeder, 2001; Naar et
al., 1999; Rachez et al., 1999]. CBP/p300 was identified
as a coactivator for NRs [Chakravarti et al., 1996] and is
considered a transcriptional integrator which is recruited
to the NRs and other transcription factors through their
association with other coactivators (e.g., the SRCs and
NCoA6(NRC)) [Chan and La Thangue, 2001; Chen et
al., 1997; Goodman and Smolik, 2000; Mahajan and
Samuels, 2000;Tian et al., 2006;Torchia et al., 1997].
Mechanistically, coactivators are thought to act by
modifying chromatin structure and/or through direct
interaction with components of the TFIID basal
transcription apparatus [Baek et al., 2002; McKenna and
O'Malley, 2002].Thus, liganded NRs bind members of
the p160 family, which recruit CBP/p300 (and CBP bound
p/CAF) to a target gene promoter.This recruitment locally
modifies chromatin structure through the CBP/p300 and
p/CAF histone acetyltransferase (HAT) activities. In
addition, members of the p160 family associate with
CARM1 (coactivator associated arginine
methyltransferase 1) and PRMT1 (protein arginine
methyltransferase 1), which potentiate receptor activation.
The effect of CARM1 and PRMT1 on receptor activity is
thought to result from chromatin changes through histone
methylation [Stallcup, 2001; Strahl et al., 2001].Thus,
PRMT1 has been shown to methylate Arg-3 of histone
H4, which enhances the extent of acetylation of H4 tails
by CBP/p300 [Strahl et al., 2001].The role of the
DRIP/TRAP complex is less well defined, although recent
studies indicate that the TRAP complex interacts with the
TAFII components of the TFIID complex and affects both
basal activity and stimulation of transcription by activators
[Baek et al., 2002]. Chromatin immunoprecipitation assays
(ChIP) indicate that p160 coactivators and CBP/p300 are
recruited to NR target genes rapidly (30 min to 1 h) after
ligand binding [Sharma and Fondell, 2002]. DRIP/TRAP
is subsequently recruited to the receptor-bound promoter
and ChIP assays show periodic cycling of p160
coactivators and TRAP220.These findings suggest that
p160 coactivators and CBP/p300 modify chromatin and
allow for the subsequent recruitment of the DRIP/TRAP
complex, which may target the RNA Polymerase II
apparatus [Sharma and Fondell, 2002].
Beyond the p160/SRC family and the DRIP/TRAP
complex, nearly 250 other putative coactivators have
been identified thus far (http://www.nursa.org).
Coactivators which have been extensively studied include
CBP, p300, p160 family members,
TRAP220/DRIP205/PBP, PGC-1, NRIF3 and
NCoA6(NRC) [Mahajan and Samuels, 2005].
TRAP220/DRIP205 was isolated biochemically as one
of the components of the TRAP/DRIP complex and also
by two-hybrid screening as PBP using PPARγ as a bait
[Zhu et al., 1997]. PGC-1 was isolated as a coactivator
for PPARγ involved in thermogenesis in brown adipose
tissue [Puigserver et al., 1998]. NRIF3 acts as a receptor
selective coactivator for the TRs and the RXRs and
interaction with these NRs occurs through a novel LxxIL
motif [Li et al., 1999; Li et al., 2001; Li et al., 2005]. NRC
(Nuclear Receptor Coregulator) [Mahajan and Samuels,
2000], also referred to as ASC-2 [Lee et al., 1999],
RAP250 [Caira et al., 2000], TRBP [Ko et al., 2000] and
PRIP [Zhu et al., 2000], was cloned and characterized
as a coactivator simultaneously by a number of
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has annotated human NRC and the other identical factors
(ASC-2, RAP250, PRIP and TRBP) as NCoA6 (nuclear
receptor coactivator 6) (NCBI Accession # NM_014071).
AIB3 (Amplified in Breast Cancer 3) is a N-terminal variant
of NCoA6 (NCBI Accession # 208277), which was first
identified as one of the genes on chromosome 20 that
was overexpressed in BT-474 breast cancer cells [Guan
et al., 1996]. However, in some papers NCoA6 has been
inadvertently referred to as AIB3. In the short time
following its discovery, NCoA6 has emerged as an
important coactivator not only for NRs, but also for a
number of other well known transcription factors such as
c-Fos, c-Jun, CREB, NF-kB, ATF-2, heat shock factors,
E2F-1, SRF, Rb, p53 and Stat2 [Goo et al., 2004; Hong
et al., 2004a; Hong et al., 2004b; Ko et al., 2000; Kong
et al., 2003; Lee et al., 1999; Lee et al., 2000; Mahajan
et al., 2007; Mahajan et al., 2002; Mahajan and Samuels,
2000; Mahajan and Samuels, 2005].The biological
importance of NCoA6 as an essential, non-redundant
coactivator for embryonic growth and viability is evident
from recent biochemical and genetic studies involving
NCoA6 knockout mice [Antonson et al., 2003; Kuang et
al., 2002; Mahajan et al., 2004; Zhu et al., 2003]. A wealth
of information has accumulated on NCoA6 over the past
7 years thanks to contributions from a number of
laboratories. In this review, we summarize this published
information and highlight the recent advances in our
understanding of how NCoA6 functions as a
transcriptional coregulator. For brevity, we refer to NRC,
ASC-2, RAP250, TRBP and PRIP as NCoA6, as
designated by NCBI. However, the original nomenclature
has been retained while citing a specific laboratory’s work
on NCoA6.
Cloning, domain structure, functional
organization and expression of the
nuclear receptor
coregulator/coactivator, NCoA6
Cloning
NCoA6 was cloned as NRC, ASC-2, RAP250, TRBP and
PRIP [Caira et al., 2000; Ko et al., 2000; Lee et al., 1999;
Mahajan and Samuels, 2000; Zhu et al., 2000] by various
groups. It is interesting to note that all the groups cloned
NCoA6 by yeast two-hybrid cDNA screening using various
NRs as baits. ASC-2 was isolated from a Xenopus cDNA
library using RXR as a bait [Lee et al., 1999], RAP250
from a mouse embryo cDNA library using PPARα as a
bait [Caira et al., 2000], TRBP was cloned from a rat GC
cell library using TR as a bait [Ko et al., 2000], while PRIP
was cloned from a mouse liver cDNA library using PPARγ
as a bait [Zhu et al., 2000]. A second isoform of human
NCoA6 has been identified and is referred to as AIB3
(Amplified in Breast Cancer 3). AIB3 is believed to be a
2001 amino acid protein, which differs from NCoA6 at
their N-termini, where the first 88 amino acids of NCoA6
are replaced by 26 different amino acids in AIB3 (NCBI
Accession # AF208277).The physical isolation of AIB3
cDNA and detailed studies may reveal some functional
differences between the two. Our laboratory cloned NRC
[Mahajan and Samuels, 2000] from a GH4C1-derived
cDNA library using full length TR as a bait. Both structural
and functional studies carried out in detail in our
laboratory and others demonstrated that NCoA6 functions
as a coactivator for NRs.
Protein domain structure and functional
organization of NCoA6
Human NCoA6 is a ∼250 kDa protein containing 2063
amino acids, while mouse NCoA6(PRIP) is a protein of
2068 amino acids [Zhu et al., 2000].The rat genome
database has recently annotated a sequence for rat
NCoA6(NRC) mRNA with a predicted protein of 1844
amino acids.The identity among human, mouse and rat
NCoA6(NRC) is over 90% at the amino acid level.
Structure-function analysis of human NCoA6(NRC) in
yeast and in mammalian cells [Mahajan and Samuels,
2000] has revealed a modular structure for NCoA6(NRC)
(Figure 1) consisting of: 1) a potent activation domain
(AD1), 2) a second Glu-, Pro-rich activation domain (AD2)
involved in NR signaling, 3) LxxLL-1, which plays an
essential role for ligand-dependent interactions with a
wide variety of NRs and LxxLL-2, which is more limited
in its NR interactions, 4) a dimerization region and 5) an
inhibitory region at the C-terminus rich in Ser, Thr, and
Leu. AD1 of NCoA6(NRC) is localized towards the
N-terminus of NCoA6(NRC) and is highly Glu- and
Pro-rich and moderately high in Gly, Asn and Ser amino
acids. AD1, encompassing 481 amino acid residues
(amino acids 302 -783), is a potent activator in
mammalian cells and is functionally as potent in activity
as the Herpes Simplex VP16 activation domain. Although
it is generally believed that Glu-rich sequences are
potential activating motifs in eukaryotes, the first 302
amino acids of NCoA6(NRC) flanking the AD1 and
containing a Glu stretch (34 residues) does not function
as an autonomous activation domain when expressed in
mammalian cells as a Gal4-DBD fusion [Mahajan and
Samuels, 2000]. Interestingly, AD1 was not found to be
necessary for NR activation [Mahajan et al., 2007]. AD2,
containing 184 residues (amino acids 940-1124), is
juxtaposed to the LxxLL-1 region, which is very rich in
Glu and Pro amino acids.This Glu/Pro rich region is
necessary for AD2 activity [Mahajan and Samuels, 2000].
Interestingly, the AD2 domain was found to be essential
for NR signaling and AF2-dependent enhancement of
NRs by NCoA6(NRC) [Mahajan et al., 2007].The
C-terminal end of NCoA6(NRC) (∼600 amino acids)
contains a region we designated as STL, which is rich in
Ser, Thr and Leu.The STL region is inhibitory in the
context of full length NCoA6(NRC) and its deletion
enhances the intrinsic activation potential of AD1 and
AD2 in NCoA6(NRC) [Mahajan and Samuels, 2000].
Thus, the role of the STL domain may be to control the
transcriptional output of NCoA6(NRC) through inter- and
intramolecular interactions.The STL region contains 9
predicted protein kinase A phosphorylation sites in two
clusters and 14 predicted casein kinase II phosphorylation
sites in four clusters.Thus, the function of the STL region
may potentially be modulated by
phosphorylation-dephosphorylation, which could alter the
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C-terminal region of NCoA6(NRC) does not contain any
apparent leucine zipper-like motifs. However, the high
content of Leu, Ile and Val may facilitate certain
hydrophobic-driven interactions of NCoA6(NRC) with
other proteins to regulate the activation potential of
NCoA6(NRC) in vivo. At this juncture, experimental
evidence for any posttranslational modification in the
C-terminus is lacking.
LxxLL modules as NR interaction motifs (NR boxes) have
been identified in most of the coactivators. p160 family
members contain multiple LxxLL modules, all of which
interact with a variety of NRs, albeit with some differences
in specificity [McInerney et al., 1998]. Barring one initial
report with NCoA6(ASC-2), which suggested that NRs
interact through a region of NCoA6(ASC-2) (amino acids
586-860) that did not contain any LxxLL motif [Lee et al.,
1999], all other studies confirmed that of the two LxxLL
motifs in NCoA6, LxxLL-1 is necessary for interaction
with a wide spectrum of NRs including TRs, RXRs, RARs,
GR, ERs, VDR and the PPARs [Caira et al., 2000; Ko et
al., 2000; Mahajan and Samuels, 2000]. Mutation of
LVNLL (LxxLL-1) to AVNAA or to AVNAL or to LVAAA
abrogated the association of NCoA6 with NRs in vitro
[Caira et al., 2000; Ko et al., 2000; Mahajan and Samuels,
2000] and in vivo [Mahajan and Samuels, 2000].Through
the use of combinatorial peptide libraries, LxxLL modules
have been characterized as Class 1, 2 or 3 depending
on the nature of the amino acid residue at position -1 or
-2 of LxxLL (LxxLL=+1+2+3+4+5, respectively) [Chang
et al., 1999].The Class 2 LxxLL module with a Pro at -2
has been shown to interact with various NRs.The LxxLL-1
region of NCoA6(NRC) (LTSPLLVNLLQSDIS) resembles
the Class 2 LxxLL module and contains a Pro at the -2
position. Members of the p160 family of coactivators
contain multiple Class I LxxLL modules (SRLxxLL), all of
which associate with a variety of NRs, albeit with some
difference in specificity. In contrast, NCoA6(NRC)
contains a single functional LxxLL-1 module that
associates with a variety of NRs in vitro and in vivo with
high affinity. Interestingly, the Pro at the -2 position found
in the NCoA6(NRC) LxxLL-1 motif is also found in the
LxxLL (PILTSLL) of TRAP220/DRIP205/PBP and RIP140
LxxLL (PILYYML) motif.The NCoA6(NRC) LxxLL-1
module and surrounding amino acids is very hydrophobic
and interacts with virtually all liganded NRs with high
affinity. Helix 12 of the NR AF2 domain is critical in the
formation of an interface which contacts the NCoA6(NRC)
LxxLL-1 module. Point mutations in helix 12 of cTRα
(L398R), or deletion of helix 12, abolish the association
of the NR with NCoA6(NRC) in vitro and in vivo [Mahajan
and Samuels, 2000]. Similarly, deletion of helix 12 (last
12 amino acids) of PPARγ resulted in the abolition of the
interaction with NCoA6(PRIP) [Zhu et al., 2000].
In yeast two-hybrid assays, full-length NCoA6(NRC)
interacts with ligand-bound NRs with similar or higher
affinity than full-length SRC-1 containing multiple
functional LxxLL motifs.The NCoA6(NRC) LxxLL-1 motif
appears to display broad specificity, yet high affinity
towards a large spectrum of NRs [Mahajan and Samuels,
2000].The Ser at the -3 position (Ser884) of LxxLL-1 in
NCoA6(TRBP) has also been shown to be important for
binding with the LBDs of NRs, particularly for ERβ, TR
and RXR [Ko et al., 2002]. Although phosphorylation of
Ser 884 by MAPK in vitro reduced its interaction with
NRs, it is not known if such regulation by phosphorylation
occurs in vivo [Ko et al., 2002]. In another study, the
LxxLL-1 module was shown to associate more avidly to
mouse ERβ1 than to ERβ2, consistent with the idea that
estradiol-induced mouse ERβ1 is a more potent
transcriptional activator than mouse ERβ2 [Zhao et al.,
2005]. Studies with a ∼300 amino acid region from rat
NCoA6(NRC) containing LxxLL-1 and AD2 indicated that
LxxLL-1 enhances both ligand-dependent activity and the
intrinsic basal activity of AD2 [Mahajan and Samuels,
2000].Thus, the LxxLL-1 module of NCoA6(NRC)
embedded in AD2 influences not only the association of
NCoA6(NRC) with NRs, but also the activation potential
of AD2. As opposed to AD1, the AD2 region has now
been shown to be necessary for transcriptional activation
by NRs [Mahajan et al., 2007].
NCoA6(NRC) contains a second LxxLL motif towards the
C-terminus (EAPTSLSQLLDNSGA) designated as
LxxLL-2, which does not contain a conserved hydrophobic
amino acid residue at the -1 position [Mahajan and
Samuels, 2000]. LxxLL-2 does not interact with TR, RAR,
RXR and GR, although it interacts with ERα with ∼10-fold
lower affinity compared with LxxLL-1 [Mahajan and
Samuels, 2000]. It has also been reported that
NCoA6(ASC-2) can associate with LXR through LxxLL-2
[Lee et al., 2001;Toresson et al., 2004]. Interestingly,
LxxLL-2 does not resemble any of the known LxxLL motifs
identified thus far in various coregulators or from
combinatorial phage peptide libraries [Chang et al., 1999].
Homodimerization region in NCoA6
NRs activate transcription from target genes preferably
as homodimers (ER, GR, PR) or heterodimers (TR, RAR,
PPAR, VDR, LXR, FXR) with RXR [Aranda and Pascual,
2001]. p160 family coactivators contain multiple LxxLL
motifs; thus a single molecule of p160 coactivator, via its
LxxLL motifs, interacts directly with various NR dimers
[Nolte et al., 1998]. Similarly, TRAP220, as a monomer
with two LxxLL motifs, one of which primarily interacts
with RXR, while the other interacts preferentially with
VDR or TR [Ito and Roeder, 2001], has the potential to
bind NR/RXR heterodimers [Ito and Roeder, 2001]. In
contrast, NCoA6 contains a single essential LxxLL-1 motif
that is involved in interaction with most of the NRs. An
interesting question relates to how NCoA6 with a single
LxxLL-1 motif binds to and activates NR dimers? Recent
studies suggest the formation of NCoA6(NRC)
homodimers, which have been shown to occur using both
yeast two-hybrid and in vitro binding assays [Mahajan
and Samuels, 2000].The homodimerization region (DD)
(Figure 1) of NCoA6(NRC) has been mapped to 146
amino acids (amino acid 849-995 of human NCoA6(NRC)
and the corresponding homologous sequence in rat
NCoA6(NRC) [Mahajan et al., 2007; Mahajan and
Samuels, 2000]. Embedded in this region is the LxxLL-1
motif, which is involved in NR interaction, but not
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Review Nuclear receptor coactivator NCoA6(NRC) in biologyFigure 1.  Domain organization of NCoA6(NRC). NCoA6(NRC) contains two activation domains (AD1 and AD2) and two LxxLL receptor interacting
motifs (LxxLL-1 and LxxLL-2). LxxLL-1 interacts with a wide variety of NRs, while LxxLL-2 is more restricted in NR recognition.The C-terminal region
of NCoA6(NRC) is rich in Ser, Thr and Leu (STL), and appears to function to repress the activation domains of the protein. NCoA6(NRC) forms
homodimers through a dimerization domain (DD), which is located near LxxLL-1. Factors that are known to be regulated by NCoA6(NRC) are also
listed.
homodimerization of NCoA6(NRC), as suggested by
mutational analysis and dimerization data.Thus, a
homodimer of NCoA6(NRC) with two LxxLL-1 motifs has
the potential of binding NR homo- and hetero-dimers with
high affinity [Mahajan et al., 2007; Mahajan and Samuels,
2000].
Conformational change in NCoA6
It is well known that ligand binding induces a
conformational change in NRs which renders them
transcriptionally active. For example, the TR-LBD
undergoes a conformational change upon ligand binding
which is necessary for binding of the LBD with LxxLL
modules of coactivators [Aranda and Pascual, 2001]. It
is an interesting paradigm to study the regulation of
activity of transcription factors and other proteins through
conformational transitions which may render the
molecules active, inactive, stable, unstable or induce
complex formation or signal transduction.Thus, the
activation properties of a coactivator could be modulated
or fine tuned through conformational alteration if the
activation domain of the coactivator molecule is buried
or unexposed when not engaged with ligand-bound NR.
Whether ligand-bound NR leads to a conformational
transition of the coactivator from a relatively inactive to
active form has been studied in NCoA6(NRC). LexA-NRC
(NRC containing AD1 and AD2 activation domains) when
expressed in yeast was not found to be constitutively
active, however, 100 fold activation was detected when
RXR without any heterologous activation domain was
co-expressed in the presence of its ligand.Thus, yeast
two-hybrid assays were used to provide evidence that
association with ligand-bound NR leads to a change in
NCoA6(NRC) which exposes its activation domains.
Similar evidence for a conformational change in
NCoA6(NRC) by liganded NR was also provided by
experiments in mammalian cells.When a region of
NCoA6(NRC) containing LxxLL-AD2 was expressed in
mammalian cells, it was found to be only moderately
active when expressed alone. However, its activity is
markedly enhanced when co-expressed with the liganded
TR-LBD [Mahajan and Samuels, 2000]. It is already
known that the LBD of liganded TR binds a single LxxLL
motif of a coactivator through the hydrophobic groove of
the liganded-LBD [Nolte et al., 1998], with the enhanced
activation suggesting a conformational change in
NCoA6(NRC) leading to enhanced AD2 activity. Similarly,
PGC-1 has been shown to undergo a conformational
change upon NR binding [Puigserver et al., 1999].Thus,
like NRs which undergo a conformational change when
they bind their cognate ligands, the activity of certain
coactivators appears to be masked until they associate
with ligand-bound NR.
NCoA6 mRNAs, isoforms, and expression
pattern
Analysis of the gene organization of human
NCoA6(RAP250) on chromosome 20q11 predicted a
single gene that spans ∼111 kb and consists of 15 exons
and 14 introns [Antonson et al., 2004].Thus, the various
sized NCoA6 mRNAs identified in different tissues likely
represent alternative splicing products of the NCoA6
gene.The sequence of NCoA6(RAP250) gene promoter
indicates that the promoter is TATA-less and contains 4
predicted binding sites for Sp1, and sites for C/EBP and
Myc/Max [Antonson et al., 2004], suggesting that the
gene might be modulated by growth regulatory signals.
The mouse gene is localized on chromosome 2 (H2) with
13 exons [Zhu et al., 2000], while rat NCoA6 resides on
chromosome 3 (q42).
NCoA6 is a 250 kDa protein expressed from an mRNA
of ∼8-9 kb in various human tissues which include spleen,
thymus, testis, ovary, peripheral blood leukocytes and
brain [Mahajan and Samuels, 2000]. NCoA6 mRNAs of
6.8 kb, 4.5 kb and 3.6 kb of varying abundance were also
detected in these tissues [Mahajan and Samuels, 2000].
Interestingly, the 3.6 kb transcript was the predominant
NCoA6 mRNA species detected in heart and skeletal
muscle, while the 4.5 kb transcript was the major form
found in testes [Mahajan and Samuels, 2000]. Mouse
NCoA6(PRIP) (∼8-9 kb mRNAs) encodes a protein of
2068 amino acids [Zhu et al., 2000].The 4.5 kb mRNA
species found in human testis was identified as an
alternatively spliced form of human NCoA6(RAP250)
encoding 1070 amino acids (1-971 and 1965-2063) [Caira
et al., 2000].This isoform lacks LxxLL-2 and a large
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Review Nuclear receptor coactivator NCoA6(NRC) in biologyFigure 2.  NRC associates with a number of cofactors in vitro and in vivo that have been characterized. Schematic of NCoA6(NRC) to indicate
the regions of NRC(NCoA6) which have been reported to associate with the indicated factors such as CAPER, CBP/p300, CoAA, DNA-PKc, DRIP130,
NIF-1 and PIMT in vitro and/or in vivo. E1A was shown to block NRC activity (Mahajan and Samuels, 2000), although its direct interaction with NRC
has not been checked. EIA is known to associate with CBP.
component (amino acids 972-1964) of the C-terminus. A
partial cDNA (rNRC.1) encoding the LxxLL-1 and AD2
followed by a stop codon and a poly A tail was isolated
from a rat pituitary GH4C1 cell cDNA library [Mahajan
and Samuels, 2000].The presence of rNRC.1 suggests
an mRNA lacking LxxLL-2 and the entire C-terminus
containing the STL region, and likely represents one of
the shorter NCoA6(NRC) isoforms expressed in the
pituitary. Since the C-terminal STL region appears to
harbor an inhibitory domain, shorter isoforms lacking this
region may have elevated intrinsic activity in vivo.The
rat genome database has recently annotated a sequence
for rat NCoA6 mRNA that encodes a predicted protein of
1844 amino acids. However, the assembled rat NCoA6
protein lacking parts of AD2 and the C-terminal STL
region is presently hypothetical.
The identity among human, mouse and rat NCoA6 is over
90% at the amino acid level.The distribution of NCoA6
protein in mice has been studied by immunochemistry
using antibody against NCoA6(RAP250) and
AIB3/NCoA6.These studies indicate that relatively higher
levels of NCoA6 are present in cells of endocrine target
tissues, including testicular sertoli cells, follicular
granulosa cells and epithelial cells of the prostate, uterus,
mammary gland, as well as kidney tubules [Zhang et al.,
2003]. NCoA6 protein expression was also detected in
thyroid and parathyroid cells and the pancreatic islets of
langerhans. Although medium to low expression was
reported in a variety of tissues, the relatively higher levels
of NCoA6 observed in reproductive and many types of
endocrine tissues suggests that NCoA6 supports NR
functions in reproduction and regulation of the endocrine
system [Zhang et al., 2003]. It should be noted that in
these studies expression has been studied using
antibodies that do not distinguish between NCoA6 and
AIB3 isoforms.
Dominant negative forms of NCoA6 and
NCoA6-siRNA
One of the ways to study the nature of a coactivator
molecule is by expressing its dominant negative form and
studying its effects. Alternatively, the biological role of a
coactivator can also be assessed by using a siRNA to
extinguish expression of the coactivator in vivo. A region
of NCoA6 containing an NR-interaction domain has been
successfully used as a dominant negative inhibitor. Since
a broad spectrum of NRs bind LxxLL-1 of NCoA6, the
ectopic expression of a region of NCoA6 containing
LxxLL-1 blocks ligand-dependent activation by NRs.
These dominant negative constructs work very well in
cell culture studies [Mahajan et al., 2007]. A peptide with
80 amino acids (DN1) of NCoA6(ASC-2) containing
LxxLL-1 when expressed in transgenic mice was found
to block activation by NRs [Kim et al., 2002].Transgenic
expression of another region (DN2) (amino acids
1431-1511) containing the LxxLL-2 region of
NCoA6(ASC-2) was found to block the activity of LXRs
in vivo [Kim et al., 2003]. An unexpected result of the
transgenic expression of DN1 or DN2 was that these
factors were reported to selectively block the activity of
endogenous NCoA6(ASC-2), but not other coactivators.
Since DN1 containing LxxLL-1 and DN2 containing
LxxLL-2 would be expected to compete with the binding
of other coactivators for liganded NRs, the mechanism(s)
by which these LxxLL regions specifically block the activity
of NCoA6(ASC-2), but not other coactivators, is unclear
and requires further study. However, these transgenic
studies have provided clues to the probable biological
role of NCoA6(NRC) in vivo.The livers from the DN2
transgenic mice showed similar changes as seen in livers
from LXRα
-/- mice, suggesting that NCoA6(NRC) plays a
role in cholesterol and lipid metabolism in the liver,
presumably through regulation of LXR [Kim et al., 2003].
More recently, a number of laboratories have used
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culture studies to attenuate the expression of NCoA6 in
vivo to study transcription factors that are regulated by
NCoA6. For example, p53 and Sox9 were found to be
regulated by NCoA6(NRC), as suggested by siRNA
studies [Mahajan et al., 2007]. siRNA against
NCoA6(ASC-2) was used in MCF-7 cells to demonstrate
the E2-dependent induction of pS2 gene expression [Ju
et al., 2006].
AIB3/NCoA6 is amplified and overexpressed in
various cancers
Human NCoA6 is localized on chromosome 20 (20q11).
The AIB3 gene was initially mapped to the 20q11 segment
of chromosome 20 during a search for amplified and
overexpressed genes mapping to chromosome 20q in
breast cancer [Guan et al., 1996]. Subsequently, using
FISH analysis, the NCoA6(ASC-2) copy number was
found to be increased to a moderate level (4-6 copies) in
14 out of 335 (4.2%) cases of breast cancer and to a high
level (>6 copies) in 15 out of 335 (4.5%) cases of breast
cancer [Lee et al., 1999]. In addition, NCoA6(ASC-2)
mRNA was also detected in 11 different breast cancer
cell lines, with the highest expression in BT-474 cells [Lee
et al., 1999].The NCoA6(ASC-2) gene was also found
to be amplified in lung and colon cancers.The high level
of NCoA6 expression in breast cancer cell lines does not
correlate with the level of ER expression. It should be
noted that the probes used to assess gene amplification
or mRNA expression do not differentiate between AIB3
and NCoA6(ASC-2) mRNAs.Therefore, it is unclear
whether it is AIB3 or NCoA6 (or both) which is
overexpressed in these tumors. Amplification and
overexpression of NCoA6/AIB3 in various cancers
underscores its functional importance (discussed later)
as a prosurvival gene necessary for normal growth and
development.
NCoA6 interacts with and forms
complexes with a variety of transcription
factors
Central to the mechanistic basis of ligand-dependent
transcriptional activation by NRs and coactivator function,
is the identification of factors which interact with
coactivators and form components of a functional
coactivator protein complex(es). Recently, a number of
laboratories have identified proteins that interact with
NCoA6 employing yeast two-hybrid screens or
biochemical purifications (Figure 2 and Figure 3). Since
NCoA6 is a large protein with multiple domains, it is likely
that distinct regions of NCoA6 might associate with factors
involved in transcription, such as transcriptional activators,
components of the basal transcription apparatus, the
DRIP/TRAP complex or chromatin remodeling factors.
Thus, like CBP, NCoA6 may act as a transcriptional
co-integrator through its interaction with a variety of
transcription factors, including the NRs. Consistent with
this model, NCoA6 plays a role in activating not only NRs,
but other factors (see Figure 1) such as c-Fos, c-Jun,
NF-kB, ATF-2, CREB, heat shock factors, SRF, Rb, p53
and Stat2 [Goo et al., 2004; Hong et al., 2004a; Hong et
al., 2004b; Ko et al., 2000; Lee et al., 1999; Lee et al.,
2000; Mahajan et al., 2007; Mahajan et al., 2002; Mahajan
and Samuels, 2000].The remainder of this section
reviews the factors that have been identified to interact
with and play a role in the action of NCoA6(NRC).
Figure 3.  NCoA6(NRC) is a component of three nuclear protein
complexes. Three protein complexes referred to as ASCOM (Goo et
al., 2003), ALR (Issaeva et al., 2007) and PTIP (Cho et al., 2007) have
been purified and the polypeptides that represent each complex are listed.
The 3 complexes share NCoA6 and several other polypeptides. Recently,
WDR5 has also been shown to be present in ASCOM (Lee et al., 2006).
CBP/p300
NCoA6 has no apparent histone acetyltransferase (HAT)
domain or HAT activity, although this has not been
rigorously examined. However, NCoA6 could modulate
chromatin structure by recruiting factors with HAT activity
to the promoter (e.g., CBP/p300). Consistent with this
notion is the finding that NCoA6(NRC) forms a high affinity
complex with CBP (Figure 2) in vivo [Mahajan and
Samuels, 2000]. Expression of NCoA6(NRC) in 293 cells
followed by extraction, affinity adsorption and Western
blotting indicated that a significant amount of CBP in the
cell is associated with NCoA6(NRC). Association of
NCoA6(NRC) with CBP involves the C-terminal region of
NCoA6(NRC), which includes AD2. p300 could not be
detected in the same Western blot, suggesting that
NCoA6(NRC) might preferentially associate with CBP in
vivo [Mahajan and Samuels, 2000].This preferential
association may in part reflect the non-redundant
physiological functions of CBP and p300. Although
NCoA6(NRC) associates with CBP in mammalian cells,
no direct association between full length NCoA6(NRC)
and full length CBP was identified in yeast [Tian et al.,
2006].This suggests that the association of NCoA6(NRC)
with CBP in mammalian cells may be mediated through
another factor. In contrast with these findings, another
study reported that NCoA6(ASC-2) associated with
various regions of CBP in yeast and by in vitro binding,
although full length CBP was not examined [Lee et al.,
2001]. Other in vitro binding studies indicated that the
C-terminal region of p300 (amino acids 1661-2414) can
associate with the C-terminal region of NCoA6(TRBP)
[Ko et al., 2000].Whether association of NCoA6 with
CBP/p300 is essential for ligand-dependent activation by
NRs or other transcription factors activated by NCoA6
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-/- cells.
However, ligand-dependent activation of NRs by
NCoA6(NRC) was completely blocked by expression of
E1A, which is known to inactivate CBP/p300 [Mahajan
and Samuels, 2000]. Earlier interaction studies indicated
a direct interaction between NR and CBP [Chakravarti et
al., 1996]. However, it is now believed that CBP is a
component of a large coactivator complex containing a
primary coactivator that directly interacts with NRs.
NCoA6(NRC) or SRC-1 was shown to primarily bind to
TRβ2-LBD, while CBP was found to associate with the
N-terminal AB domain of TRβ2 [Tian et al., 2006]? .Thus,
in a concerted manner, binding of both NCoA6(NRC) and
CBP may lead to a maximum transcription potential of
certain NRs.These results support the notion that
NCoA6(NRC) may act as a coactivator by recruiting a
complex containing CBP/p300 and associated factors to
ligand-bound NRs on gene promoters.
DNA repair components and methyl
transferase-containing protein complexes: PTIP,
ASCOM, ALR/MLL2 complex
Some recent studies have hinted that NCoA6 may be
involved in DNA repair. At this juncture, most of the clues
come from interaction studies. For example, the
NCoA6(TRBP) C-terminal region (amino acids 1237-2063)
has been shown to associate in vitro with some
components of the DNA-dependent protein kinase
complex [Ko et al., 2000].The components included the
catalytic subunit (DNA-PKc) (Figure 2), regulatory
subunits (Ku70 and Ku80), poly(ADP-ribose)-polymerase
(PARP), NuMA (p200) and DNA topoisomerase I.
DNA-PK in vitro phosphorylates NCoA6(TRBP) containing
amino acids 714-999 in a DNA-dependent manner and
amino acids 1237-2063 in a DNA-independent manner
[Ko et al., 2000]. In addition, NCoA6(TRBP) activates
DNA-PK in vitro which has a phosphorylation pattern that
differs from its DNA-mediated activation form. Although
the role of DNA-PK in recombination and DNA repair has
been very well characterized [Nishino and Morikawa,
2002], the involvement of DNA-PK in transcription is less
clear. However, studies of NCoA6(TRBP) activity in cells
deficient in DNA-PK indicate a marked reduction in
NCoA6(TRBP)-mediated enhancement of GR activity,
suggesting a role for DNA-PK in transcriptional activation
[Ko and Chin, 2003]. A protein called PTIP (Pax
transactivation domain-interacting protein), believed to
be involved in DNA damage response upon ionizing
radiation, associates with a Set1-like histone
methyltransferase component consisting of ∼9
polypetides, including NCoA6 [Cho et al., 2007]. NCoA6
was also shown to localize to NucE (nucleosome of pS2
promoter containing ER binding site) containing
TopoIIβ-mediated double strand breaks [Ju et al., 2006].
A steady state ∼2 MDa complex referred to as ASCOM,
consisting of ∼8 proteins was isolated from HeLa nuclei
using antibody against NCoA6(ASC-2) [Goo et al., 2003].
In addition to NCoA6(ASC-2), the complex includes the
Trithorax-related proteins ALL-1/MLL, ALR-1(MLL2),
ALR-2, HALR (MLL-3), ASH2, the 66 kDa retinoblastoma
binding protein, RBQ3 and 48 kDa α- and β-tubulin
proteins (Figure 4).WDR5 was recently added to the list
of polypetides that are present in ASCOM [Lee et al.,
2006]. Given the composition and the nature of proteins
associated with NCoA6(ASC-2), the ASCOM complex is
clearly distinct from other known coactivator complexes
identified for NRs and other transcription factors. How
ASCOM acts to regulate transcription is not known,
although recombinant ALR-1 and HALR exhibit weak
histone H3 lysine 4 methylation activities in vitro. Using
ChIP assays, ASH2, ALR and NCoA6(ASC-2) were
reported to be recruited to the RARβ and the p21
WAF1
gene promoters which are activated by liganded RAR,
and this recruitment was inhibited when the DN1 dominant
negative peptide containing LxxLL-1 was expressed [Goo
et al., 2003]. DN1 did not affect the recruitment of
TRAP220 or SRC-1 to the p21
WAF1 promoter.This is
surprising since NCoA6(ASC-2), TRAP220 and all the
p160 coactivators are thought to use the same interaction
surface of liganded-RAR. Although the mechanism of
such specific inhibition is unclear [Goo et al., 2003], a
possible explanation is that the DN1 LxxLL-1 region
blocks dimerization of NCoA6, thus preventing its binding
to NR dimers [Mahajan and Samuels, 2000].
Recently, NCoA6 was reported to be a component of
multiprotein ALR [Issaeva et al., 2007] and PTIP [Cho et
al., 2007] complexes (Figure 3). PTIP complex contained
ASH2L, RbBP5 (RBQ3), WDR5, hDPY-30, MLL3, MLL4,
PA1 and NCoA6. In the ALR complex, 12 distinct
polypeptides were identified as UTX, PTIP, Matrin 3,
ASH2/1, RBQ3, ASH2/2, MGC4606, WDR5, DPY30, α-
and β-tubulin and NCoA6 [Issaeva et al., 2007].
Interestingly, all the complexes containing NCoA6 contain
Set proteins as core components, which harbor
methyltransferase activity involved in histone, H3K4
methylation of chromatin. However, NCoA6 was not found
to be present in partially purified ER-MLL2 complex [Mo
et al., 2006].The composition of these complexes is
similar but not identical, invoking the possibility that
association of NCoA6 with these complexes may be
regulated in a cell type- or target gene-specific manner.
It is unclear whether NCoA6 acts only through these
complexes to activate NRs and other transcription factors
such as c-Fos, c-Jun, CREB and NF-kB.
Although NCoA6 was shown to be a component of the
ASCOM, ALR and PTIP complexes, CBP/p300 and a
number of other NRC-interacting factors referred to as
NIF-1 [Mahajan et al., 2002], CoAA [Iwasaki et al., 2001],
CAPER [Jung et al., 2002] and PIMT [Zhu et al., 2001]
have been identified as NCoA6-interacting proteins which
may play important roles in the action of NCoA6.
However, as of now, none of these factors have been
shown to be a component of any known coactivator
complex.
NIF-1 and NIF-2
NRC-interacting factor-1 (NIF-1) was isolated in a yeast
two-hybrid screen as an NRC-interacting factor (Figure
2) [Mahajan et al., 2002]. NIF-1 is a zinc finger protein
which is highly conserved across avian, mouse, rat, and
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+/- mice exhibit a wound healing defect. Shown is a representative mouse with skin lesions in the neck and grooming
area.The skin from the wound site, edge of the wound and a normal skin area was processed for histology and stained with hematoxylin-eosin.The
skin lesions show an increase in sebaceous glands, a lack of hair follicles and no keratinocyte migration (Epithelial Tongue). Reproduced with permission
from Mahajan et al. (Mahajan et al., 2004) by the American Society of Microbiology (Mol. Cell. Biol.).
human species. Human NIF-1 is a 1342 amino acid
nuclear protein which contains a number of highly
conserved domains including six zinc fingers, an
N-terminal acidic rich region, an LxxLL and a C-terminal
leucine zipper-like motif.The LxxLL motif of NIF-1 does
not directly interact with Type I or Type II NRs [Mahajan
et al., 2002; Mahajan and Samuels, 2005]. Human NIF-2
was identified as an alternatively spliced isoform that is
identical to NIF-1, but lacks the first three zinc fingers
[Mahajan et al., 2002]. NCoA6(NRC) associates with
NIF-1 through a region containing 146 amino acids (amino
acids 849-995) of NCoA6(NRC) referred to as the
NIF-interaction domain (NIF-ID). NIF-1 interacts with
NCoA6(NRC) through a region containing zinc finger 6.
Although the NIF-ID of NCoA6(NRC) contains LxxLL-1,
this motif is not directly involved in interaction with NIF-1
[Mahajan et al., 2002]. It is interesting that although the
NIF-ID and the NR interaction region of NCoA6(NRC)
are in close physical proximity (Figure 2), associations of
NIF-1 and NRs with NCoA6(NRC) are not mutually
exclusive.
Zinc fingers 1, 2 and 3 in NIF-1 form a unique structure
referred to as BED fingers [Aravind, 2000], a motif
conserved in Drosophila BEAF and DREF [Hart et al.,
1999] and several other eukaryotic transcription factors
such as Sp1 [Ishii and Laemmli, 2003]. BED finger
proteins are thought to function as either activators or
repressors by modifying local chromatin structure upon
binding to GC-rich sequences [Aravind, 2000].Thus,
NIF-1 may modulate chromatin structure as a part of a
coactivator complex and facilitate the activation potential
of NRs and other factors. Another possibility is that NIF-1
may also bind insulator DNA sequences directly and
facilitate the process of transcription. Interestingly, NIF-2
lacks the BED fingers, but retains the ability to bind
NCoA6(NRC) through zinc finger 6.This raises the
possibility that NIF-2 may be a naturally-occurring
dominant negative form of NIF-1, although this has not
been verified experimentally. Both NIF-1 and NIF-2 are
ubiquitously expressed in a number of human tissues,
although NIF-1 mRNA levels are expressed at much
higher levels than NIF-2 [Mahajan et al., 2002]. NIF-1
contains a number of potential phosphorylation sites for
various kinases which may play a role in modulating the
function of NIF-1. Although NIF-1 does not directly interact
with ligand-bound NRs, it markedly enhances
ligand-dependent activation [Mahajan et al., 2002]. In
addition to NRs, NIF-1 enhances the transcriptional
activity of c-Fos, c-Jun and p53 [Mahajan et al., 2007;
Mahajan et al., 2002].Thus, NIF-1 displays an activation
profile somewhat similar to NCoA6(NRC) and interacts
with NCoA6(NRC) in vivo. Since NIF-1 does not directly
bind to NRs, its action is likely through its association with
a primary coactivator such as NCoA6(NRC). Factors like
NIF-1, which do not directly bind transcriptional activators
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bind transcriptional activators (NRs and other transcription
factors), have been referred to as co-transducers
[Mahajan et al., 2002; Mahajan and Samuels, 2005].
RNA binding proteins, CAPER, CoAA and PIMT
CAPER, PIMT and CoAA were identified in yeast
two-hybrid screens to interact with NCoA6 (Figure 2). In
contrast with NIF-1, CAPER, CoAA and PIMT contain
RNA recognition motifs (RRMs). Although the extent of
activation of NRs by PIMT, CAPER and CoAA is only
moderate (1.8-3 fold), this does not exclude important
roles for these factors since many established
coactivators only moderately enhance activation in
transfection assays. CAPER (Coactivator protein for AP-1
and ER receptor) was isolated from a mouse liver cDNA
library using the C-terminal region (amino acids
1172-1729) of NCoA6(ASC-2) as bait [Jung et al., 2002].
CAPER is identical to the nuclear autoantigens HCC1.3
and HCC1.4 reported in hepatocarcinoma [Imai et al.,
1993]. HCC1.3 and HCC1.4 are identical except for 6
additional amino acids in HCC1.4. Mouse CAPER
(HCC1.3) was reported to enhance activation of ERα and
c-Jun. CAPER contains three RRMs and associates with
c-Jun and the ligand-bound ER-LBD region via RRM3,
while the C-terminus of CAPER was shown to bind
NCoA6(ASC-2) [Jung et al., 2002]. CAPER did not appear
to enhance activation of other NRs such as RARs, RXRs,
TR and GR.The basis for ER specificity was not clarified,
but the specificity implies that CAPER may not enhance
ER function through association with NCoA6(ASC-2),
which interacts with and enhances activation of NRs
including RARs, RXRs, TR and GR.
Another RRM-containing factor referred to as “Coactivator
activator” (CoAA) is a 669 amino acid protein isolated
from a GC cell cDNA library in a yeast two-hybrid screen
using the C-terminal region (amino acids 1641-2063) of
NCoA6(TRBP) as bait [Iwasaki et al., 2001]. CoAA
contains two RRMs near its N-terminus, while its
C-terminal region interacts with NCoA6(TRBP).Whether
CoAA directly interacts with various NRs has not been
examined. Expression of CoAA enhances activation by
a number of transcription factors including NF-kB, CREB,
AP-1, TR, ER and GR. CoAA was also shown to
associate with DNA-PK regulatory subunit Ku86 and
PARP from GH3 cells, suggesting that CoAA may exist
as part of a DNA-PK/NCoA6 complex in vivo.
PIMT (PRIP-interacting methyltransferase) was also
isolated in a yeast two-hybrid screen from a human liver
cDNA library with the bait containing the C-terminal region
(amino acids 773-2067) of NCoA6(PRIP) [Zhu et al.,
2001]. PIMT is a ubiquitously expressed putative RNA
methyltransferase which contains an invariant GXXGXXI
motif near its N-terminus found in K-homology motifs of
many RNA binding proteins. Expression of PIMT
enhances the activity of PPARγ and RXR, which is further
enhanced by expression of NCoA6(PRIP).The putative
methyltransferase activity of PIMT does not appear to be
involved in its role as an activator since deletion of the
methyltransferase domain does not affect its activating
function [Zhu et al., 2001]. Expression of PIMT enhances
activation by PPARγ and RXR. Like NCoA6(NRC), PIMT
homodimerizes in vitro and may also form
homo-oligomers [Zhu et al., 2001]. PIMT does not appear
to methylate histones, but binds CBP/p300 and
PBP(DRIP205/TRAP220) [Misra et al., 2002]. CAPER,
CoAA, PIMT, and NIF-1 were not identified as
components of the ASCOM complex [Goo et al., 2003].
DRIP130, a component of the DRIP/TRAP mediator
complex, was reported to associate with the C-terminal
region of NCoA6(TRBP) in vitro (amino acids 1237-2063)
[Ko et al., 2000].Whether DRIP130 and NCoA6
synergistically activate NRs and/or other transcription
factors has not been explored.
Role of NCoA6 in systemic biology and
physiology: NCoA6 is an essential
coactivator and a pleiotropic modulator
affecting growth, development,
reproduction, apoptosis and wound
healing
Most of the coactivators that have been characterized in
detail are complex in structure, containing multiple
domains. Although mechanistically, coactivator molecules
are primarily involved in orchestrating transcription, their
role in biological and physiological functions has become
known by knocking out their genes in mice. CBP
[Goodman and Smolik, 2000;Tanaka et al., 1997], p300
[Yao et al., 1998], SRC-1 [Xu et al., 1998],
SRC-2/GRIP1/TIF-2 [Gehin et al., 2002], SRC-3 [Xu et
al., 2000] (p160/SRC family), TRAP220/PBP [Crawford
et al., 2002; Ito et al., 2000; Landles et al., 2003], RIP140
[White et al., 2000] and (NCoA6)
NRC/AIB3/PRIP/RAP250 [Antonson et al., 2003; Kuang
et al., 2002; Mahajan et al., 2004; Zhu et al., 2003] have
been deleted in mice by homologous recombination to
gain insight into the biological role(s) of these
coactivators. Based on these studies, coactivator
molecules can be grouped into non-essential and
essential coactivators. RIP140 and p160 family members
(SRC-1, SRC-2 and SRC-3), when knocked out, are not
essential for embryonic growth and development since
mice carrying homozygous deletion of either SRC-1,
SRC-2, SRC-3 or RIP140 are viable [White et al., 2000].
Although members of the p160 family of coactivators can
mediate different functions [Gehin et al., 2002; Mark et
al., 2004], the gene deletion studies suggest redundancy
in function of the p160 coactivator family. On the other
hand, CBP, p300, TRAP220/PBP and NCoA6 null mutant
embryos do not survive beyond 12.5 dpc since these
coactivators are essential for embryonic growth and
development.
Transgenic animal model systems using
dominant negative peptides
As an alternative to gene targeting, transgenic mouse
models have been generated to address the role of
NCoA6(ASC-2) in NR signaling using a dominant negative
approach [Kim et al., 2002; Kim et al., 2003]. For example,
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motif [Kim et al., 2002] and functions as a dominant
negative inhibitor, while DN2 peptide contains the LxxLL-2
motif. NCoA6(ASC-2) associates with the majority of the
NRs through LxxLL-1, while LxxLL-2 specifically
associates with LXRs. Several transgenic mice lines,
each expressing either DN1 or DN2, were produced [Kim
et al., 2003]. DN1 transgenic lines displayed pathological
abnormalities in many different organs that included heart,
pituitary, adrenal glands, brain, spleen, liver and lung. In
particular, eyes with microphthalmia and posterior
lanticonus with cataract were scored out [Kim et al., 2002].
On a high fat cholesterol diet, DN2 transgenic lines
displayed rapid accumulation of large amounts of
cholesterol and downregulation of known lipid
metabolizing target genes of LXR [Kim et al., 2003]. Both
DN1 and DN2 caused repression of some NR-mediated
target gene expression, which was found to be completely
reversed by co-transfection of wild-type NCoA6(ASC-2),
but not by co-expression of other coactivators such as
TRAP220 or SRC-1.These results were interpreted to
indicate that DN1 and DN2 transgenic expression blocks
specific interaction of endogenous NCoA6(ASC-2) with
nuclear receptors. Recent studies on conditional knockout
of NCoA6(PRIP) in liver [Sarkar et al., 2007], however,
suggest that phenotypes observed in DN1 transgenic
mice may not be simply ASC-2-dependent. It is likely that
a broad spectrum of Type I and Type II endogenous
receptors are inhibited by DN1(LxxLL-1 peptide).Thus,
the phenotypes may result not just from inhibition of
NCoA6(ASC-2)-NR interaction, but also from inactivation
of a number of receptors that bind DN1 in vivo.Thus, the
mechanism of DN1-mediated phenotypes in transgenic
mice needs a broader interpretation.
Deletion of both NCoA6 genes is embryonic
lethal and leads to apoptosis
The NCoA6 gene has been knocked out in mice in a
mixed C57BL/6-129S6 (C57/129) genetic background
[Antonson et al., 2003; Kuang et al., 2002; Mahajan et
al., 2004; Zhu et al., 2003].These studies confirmed that
NCoA6 null mutation is embryonic lethal and mutant
embryos die in utero between 8.5-12.5 dpc, while C57/129
NCoA6
+/- mutant mice appear normal and grow similar to
wild-type mice.The cause of lethality of NCoA6
-/- embryos
is attributed to placental dysfunction and a number of
developmental defects involving the heart, liver and brain
[Antonson et al., 2003; Kuang et al., 2002; Zhu et al.,
2003].The role of NCoA6(NRC) in growth is particularly
striking since NCoA6(NRC)
-/- embryos do not survive
beyond 12.5 dpc, are growth retarded and half the size
of NCoA6(NRC)
+/- or NCoA6(NRC)
+/+ embryos [Mahajan
et al., 2004].The decreased growth could result from a
disruption in cell cycle progression, increased apoptosis,
or both. Interestingly, NCoA6(NRC)
-/- mouse embryo
fibroblasts (MEFs) derived from 12.5 dpc NCoA6(NRC)
-/-
embryos also exhibit growth retardation in culture
compared to NCoA6(NRC)
+/+ MEFs. In addition,
NCoA6(NRC)
-/- MEFs undergo apoptosis as they enter
into the late log phase of growth [Mahajan et al., 2004].
NCoA6(NRC)
+/+ MEFs do not undergo apoptosis under
the same growth conditions, while NCoA6(NRC)
+/- cells
exhibit reduced apoptosis. Knockdown of NCoA6(NRC)
in wild-type NCoA6(NRC)
+/+ MEFs using RNAi leads to
a similar extent of apoptosis as found with NCoA6(NRC)
-/-
MEFs [Mahajan et al., 2004]. Apoptosis of the
NCoA6(NRC)
-/- cells seems caspase-mediated since
zVAD-fmk, a pan-caspase inhibitor, blocks the
apoptogenic response in NCoA6(NRC)
-/- MEFs [Mahajan
et al., 2004]. However, which caspase(s) is involved and
what triggers apoptosis in these cells remain to be
identified.These findings suggest that NCoA6(NRC) is
involved in regulating antiapoptotic and/or prosurvival
genes necessary for cell growth and development.
Interestingly, growth retardation has also been observed
in MEFs derived from Trap220
-/- embryos [Ito et al., 2000].
A number of laboratories have used NCoA6
-/- MEFs to
show that activation by RXR, RAR, TR and PPAR is
compromised in NCoA6
-/- MEF cells as opposed to
wild-type cells [Antonson et al., 2003; Kuang et al., 2002;
Qi et al., 2003; Zhu et al., 2003]. Although different
laboratories have reported differences in the extent of
activation by various NRs in NCoA6
-/- MEFs, the overall
conclusion is that NCoA6 functions as a coactivator for
RXR, RAR, TR and PPAR. Also, NCoA6(PRIP)
-/- MEF
cells in culture were reported to be refractory to
PPARγ-mediated adipogenesis and fail to express
adipogenic markers like aP2.Thus, much like
PBP/TRAP220, this study concluded that NCoA6(PRIP)
is required for the adipogenic program [Qi et al., 2003].
Growth and reproductive phenotypes of
NCoA6
+/- 129S6 newborn and adult mice
Although NCoA6(NRC)
+/- mice in the C57/129 mixed
genetic background appear outwardly normal and grow
and reproduce similar to NCoA6(NRC)
+/+ mice, the
penetrance of a specific phenotype is frequently
dependent on the genetic background of the mouse strain.
Since the ES cells used for homologous recombination
are derived from the 129S6 strain, the effect of
NCoA6(NRC) heterozygosity was examined in 129S6
mice generated in our laboratory [Mahajan et al., 2004].
The NCoA6(NRC)
+/- mice in 129S6 and C57/129 mixed
genetic background exhibit a number of interesting
phenotypes, primarily involving growth, reproduction and
wound healing [Mahajan et al., 2004].
Growth retardation phenotype
NCoA6(NRC)
+/- 129S6 mice exhibit a neonatal growth
phenotype; the newborn pups are ∼10-15% smaller than
their wild-type litter mates [Mahajan et al., 2004].
However, after weaning, the NCoA6(NRC)
+/- mice exhibit
“catch-up” growth, and within 2 months these mice
become similar in size to their NCoA6(NRC)
+/+ littermates.
Although similar growth retardation has also been noted
among NCoA6(NRC)
+/- neonates in the C57/129
background, it is much less profound, and is found in less
than 5% of neonates. Interestingly, ∼3% of the
NCoA6(NRC)
+/- 129S6 newborn pups are extremely
growth stunted, weighing 70% less than their wild-type
littermates.These mice often die before weaning.
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exhibit a similar “catch-up” growth, as described earlier
[Mahajan et al., 2004]. Interestingly, the growth phenotype
found in NCoA6(NRC)
+/- 129S6 mice resembles that found
with TIF-2
-/- (SRC-2) mice, which also exhibit transient
postnatal growth retardation [Gehin et al., 2002].
However, this phenotype seems different from pCIP
-/-
(SRC-3) newborn mice that are also uniformly smaller in
size, but their weight deficit persists through adulthood.
This is thought to reflect a role for pCIP
-/- (SRC-3) in
mediating effects through the IGF-1 pathway [Liao et al.,
2002; Xu et al., 2000].The molecular mechanisms
underlying growth retardation in NCoA6(NRC)
+/- 129S6
mice have not yet been defined, but likely reflect an effect
of NCoA6(NRC) on one or more transcription factors
which play an important role in growth (e.g., AP-1).
Male and female hypofertility, and mammary glands
Although NCoA6(NRC)
+/- C57/129 mice exhibit no
reproductive phenotype, the fertility of both sexes of
NCoA6(NRC)
+/- mice in 129S6 background is
compromised [Mahajan et al., 2004]. Both male and
female mice are hypofertile (average litter size of 3 pups)
and ∼20% of NCoA6(NRC)
+/- females are sterile.These
infertile females appear to mate based on the formation
of vaginal plugs and exhibit normal estrus cycles,
suggesting problems in oogenesis, implantation of
fertilized ova, or a defect in placental function, since no
embryos were detected between 8.5-12.5 dpc.The
number of newborn NCoA6(NRC)
+/- pups obtained from
crosses between NCoA6(NRC)
+/- 129S6 hypofertile males
and females is far less than expected based on Mendelian
distribution [Mahajan et al., 2004].This appears to result
from a significant number of NCoA6(NRC)
+/- embryos
dying in utero.Those NCoA6(NRC)
+/- 129S6 female mice
which are hypofertile exhibit a progressive decline in
fertility as they age and their newborn pups have a high
rate of neonatal mortality. In another study,
NCoA6(PRIP)-deficient mammary glands [Qi et al., 2004]
during pregnancy exhibited decreased alveolar density.
It was reported that the null mammary glands could not
produce enough milk to nurse all the pups during
lactation.The results suggested that NCoA6(PRIP) is
required for efficient ductal branching of mammary glands
in response to estrogen.The reproductive phenotypes in
NCoA6(NRC)
+/- 129S6 mice are similar to those found
for TIF-2
-/- (SRC-2) mice [Gehin et al., 2002].TIF-2
-/-
males exhibit hypofertility resulting from age-dependent
testicular degeneration and defective sperm, while female
hypofertility is due to placental hypoplasia and the need
for maternal TIF-2 in the decidua stromal cells of the
placenta [Gehin et al., 2002]. Although the reproductive
phenotype of NCoA6(NRC)
+/- 129S6 mice resemble
TIF-2
-/- mice, the precise mechanism(s) underlying male
and female hypofertility in NCoA6(NRC)
+/- 129S6 mice
needs further clarification.Whether TIF-2 and NCoA6 are
needed together requires further study. It is of interest
that LXRα/β
-/- male mice become completely sterile within
6 months [Volle et al., 2004]. Since NCoA6 acts as a
coactivator for LXR [Kim et al., 2003], the progressive
loss of fertility in NCoA6(NRC)
+/- male mice may reflect
this effect of NCoA6(NRC) on the LXRs in the testes.
Recently, mice have been generated with Set domain
mutations in MLL3 to elucidate the physiological role of
ASCOM (coactivator complex that associates with
NCoA6(ASC-2) [Lee et al., 2006]. MLL3
Δ/Δ mutant mice
phenotypes are the result of the deletion of the Set
catalytic domain involved in methylation. MLL3
Δ/Δ mutation
leads to partial embryonic lethality. MLL3
Δ/Δ mice [Lee et
al., 2006] are viable and share some similar phenotypes
with NCoA6(NRC)
+/- isogenic mice [Mahajan et al., 2004].
MLL3
Δ/Δ mice were stunted in their overall growth,
weighing 30-40% less at birth and females exhibited a
range of reproductive phenotypes from infertility to
hypofertility, while males were generally hypofertile.
Interestingly, MEFs generated from MLL3
Δ/Δ strain doubled
at approximately half the rate of wild-type MEFs [Lee et
al., 2006], much like NCoA6(NRC)
-/- MEFs [Mahajan et
al., 2004].
NCoA6
+/- mice exhibit a wound healing
phenotype resulting from a defect in
keratinocyte migration
In general, NCoA6
+/- C57/129 mice appear normal,
therefore these mice have not been followed through
adulthood in some laboratories. In our laboratory, we
have followed the postnatal growth of NCoA6(NRC)
+/-
mice. As they grow older, these mice exhibit a wound
healing phenotype [Mahajan et al., 2004].The mice
spontaneously develop skin lesions or ulcers around the
neck, ears, snout and facial area (Figure 4).These
regions correspond to the areas where mice groom and
likely scratch themselves.This occurs in approximately
25% of both male and female NCoA6(NRC)
+/- C57/129,
as well as NCoA6(NRC)
+/- 129S6 mice.These
spontaneous lesions develop as early as 4-6 months of
age in the NCoA6(NRC)
+/- C57/129 mice and somewhat
earlier in the 129S6 background [Mahajan et al., 2004].
Histopathology of the affected and normal regions of the
skin show thickening of the epidermis, increased
sebaceous glands and a reduction or total loss of hair
follicles. In addition, there is no leading edge of
keratinocyte migration (Epithelial Tongue), which is seen
in normal wound healing (Figure 4).This lack of
keratinocyte migration was reproduced using ex vivo skin
explant cultures from two day old C57/129 NCoA6(NRC)
+/-
mice [Mahajan et al., 2004].While NCoA6(NRC)
+/+
keratinocytes showed robust migration when incubated
with epidermal growth factor (EGF), keratinocytes from
the NCoA6(NRC)
+/- explants showed little or no response
to EGF (Figure 5).
Interestingly, the wound healing phenotype identified in
the NCoA6(NRC)
+/- mice is similar to that observed in
mice where c-Myc is targeted to the basal layer of mouse
epidermis and hair follicles using a keratin K14 promoter
expression vector [Waikel et al., 2001]. Although mice
heterozygous for expression of K14/c-Myc are viable and
have no phenotype at birth, like the NCoA6(NRC)
+/- mice
as they age, they develop chronic skin lesions in the
facial, ear and neck grooming areas.The mechanism for
development of the c-Myc-mediated chronic wounds was
suggested to be secondary to repression of integrins (e.g.,
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+/- mice. Keratinocyte migration was determined from skin explants of
2 day old wild-type (left) and NCoA6(NRC)
+/- mice (right). Explants from NCoA6(NRC)
+/- mice exhibit a delay in the initiation of and a diminished capacity
for migration, as well as a lack of response to EGF. Reproduced with permission from Mahajan et al. (Mahajan et al., 2004) by the American Society
of Microbiology (Mol. Cell. Biol.).
α6 and β1) [Waikel et al., 2001].These integrins are
thought to play an important role in keratinocyte migration
and in self-renewal of epidermal stem cells, leading to
their gradual depletion over time.
A similar phenotype found in mice heterozygous for
expression of K14/c-Myc and in the NCoA6(NRC)
+/- mice
suggests that NCoA6(NRC) may play a role in regulating
the genes targeted by overexpressed c-Myc. For example,
NCoA6(NRC) is a potent coregulator of c-Jun activity [Ko
et al., 2000; Lee et al., 2000; Mahajan et al., 2002], which
plays an important role in regulating genes involved in
wound healing (integrins, laminins, and extracellular
matrix genes in the epithelium) [Angel et al., 2001]. In
addition, c-Jun has recently been shown to stimulate
expression of heparin-binding-epidermal growth factor
(HB-EGF) in the basal layer of wounded epithelium which,
in turn, stimulates signaling by EGFR to regulate
keratinocyte migration through regulation of focal
adhesion kinase [Li et al., 2003]. Since NCoA6 is known
to play an important role in c-Jun signaling [Ko et al.,
2000; Lee et al., 2000; Mahajan et al., 2002], the impaired
wound healing phenotype of NCoA6(NRC)
+/- mice can
be explained, at least in part, by a reduction in c-Jun
activity. In addition to c-Jun, other transcription factors
and signaling molecules (e.g., NF-kB and the PPARs)
involved in wound healing are known to be regulated by
NCoA6 [Ko et al., 2000; Lee et al., 1999; Mahajan et al.,
2002; Mahajan and Samuels, 2000; Zhu et al., 2000; Zhu
et al., 2003]. Both PPARα and PPARβ have been shown
to be important in wound healing [Michalik and Wahli,
2007;Tan et al., 2001].The precise mechanism(s) by
which a reduction of NCoA6(NRC) in the skin of
NCoA6(NRC)
+/- mice leads to chronic skin wounds needs
to be further defined. However, its role as a coactivator
for c-Jun and the PPARs, and its role as a prosurvival
antiapoptotic factor, suggests that NCoA6 acts through
regulation of one or more of the above factors and
functional pathways involved in the wound healing
process.
NCoA6
+/- mice exhibit decreased insulin
secretion
In the pancreas, NCoA6 is expressed in the endocrine
cells of islets of langerhans and thus the role of
NCoA6(ASC-2) in insulin secretion from pancreatic β-cells
has been assessed in heterozygous mice and
NCoA6(ASC-2) overexpressed in cells [Yeom et al.,
2006]. Overexpressed NCoA6(ASC-2) increased
glucose-elicited insulin secretion, whereas insulin
secretion was decreased in islets from NCoA6(ASC-2)
+/-
mice. Primary rat islets ectopically expressing DN1 or
DN2 (dominant negative fragments from NCoA6(ASC-2)
that contain NR boxes 1 and 2, respectively) exhibited
decreased insulin secretion. Islet mass and number were
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is believed to be due to increased apoptosis and
decreased proliferation of NCoA6
+/- islets [Yeom et al.,
2006].
NCoA6
+/- mice exhibit accelerated polyoma
middle-T antigen-induced mammary
tumorigenesis
In one of the studies, AIB3(NCoA6)
+/- were crossed with
mice carrying polyoma middle-T antigen (pyMT) and these
mice were directly compared with transgenic pyMT mice
for mammary tumorigenesis [Zhang et al., 2004].
Mammary tumor development in AIB3
+/- pyMT female
and male mice was substantially accelerated as compared
with that in WT/pyMT mice.Tumor formation in nude mice
that received premalignant NCoA6/AIB3
+/- pyMT
mammary tissue was much faster than in nude mice that
received transplants from premalignant WT/pyMT
mammary tissue.This tumor acceleration was reported
as being due to increased cell proliferation and ductal
hyperplasia and mammary intraepithelial neoplasia.The
mechanism of pyMT-induced tumorigenesis was believed
to be through a partial impairment of activated
PPARγ/RXR [Zhang et al., 2004].
Phenotypes from conditional knockouts
NCoA6 null mutation is embryonic lethal, which poses a
challenge in deciphering the in vivo functions of NCoA6
in adult mice.To overcome this hurdle, some laboratories
have recently produced conditional knockout mice for
NCoA6 to study the role of NCoA6 in select tissues of
adult mice. In NCoA6(PRIP)-deficient mammary glands
[Qi et al., 2004], the elongation of ducts during puberty
was not affected, but the number of ductal branches was
decreased and during pregnancy the null mammary
glands exhibited decreased alveolar density.The lactating
NCoA6(PRIP)-deficient glands contained scant
lobuloalveoli with many adipocytes, while the wild-type
glands lacked adipocytes. It was reported that the null
mammary glands could not produce enough milk to nurse
all the pups during lactation.The results suggested that
NCoA6(PRIP) contributes to efficient ductal branching of
mammary glands in response to estrogen. A slight
increase in apoptosis was found in the terminal buds from
NCoA6(PRIP)-deficient glands, raising the possibility that
abnormal apoptosis contributes to the impaired ductal
branching [Qi et al., 2004].
NCoA6(PRIP) liver conditional knockout mice have been
generated to study the in vivo role of NCoA6 as a
coactivator for PPARα and CAR [Sarkar et al., 2007].
NCoA6(ASC-2) had been earlier shown to interact with
CAR and enhance the transcriptional activation by CAR
in transfection assays [Choi et al., 2005]. Similarly, NCoA6
was shown to activate PPARs in in vitro studies [Caira et
al., 2000; Zhu et al., 2000].The in vivo data obtained from
conditional knockout studies show that NCoA6(PRIP)
deficiency in liver fails to alter acetaminophen-induced
hepatotoxicity in mice pretreated with CAR ligands
phenobarbital (PB) or TCPOBOP. No differences in the
upregulation of cytochrome P450 gene expression
(CYP1A2, CYP2B10, CYP3A11 and CYP2E1) were seen
following PB or TCPOBOP treatment between
NCoA6(PRIP)
+/+ or liver NCoA6(PRIP)
-/- conditional
knockout mice. CAR mRNA and protein levels between
these mice were found to be similar, suggesting that
NCoA6(PRIP) does not alter hepatic CAR expression
[Sarkar et al., 2007].These in vivo findings were
somewhat contradictory to earlier studies in transgenic
mice expressing DN1, a fragment of NCoA6(ASC-2)
containing the LxxLL-1 motif [Kim et al., 2002]; these mice
failed to show acetaminophen-induced hepatic necrosis.
Similarly, RAP250/NCoA6(PRIP) has been shown to
activate PPARs with in vitro studies [Caira et al., 2000;
Zhu et al., 2000]. However, in conditional knockout mice,
the degree of PPARα ligand-mediated peroxisome
proliferation in liver cells was essentially similar to that
seen in wild-type liver cells, implying that in liver, NCoA6
is not involved for PPARα-mediated proliferation. Also,
the PPARα-specific target genes fatty acyl-CoA oxidase,
enoyl-CoA hydratase/L-3 hydoxyacyl-CoA hydrogenase
(L-bifunctional enzyme; L-PBE), peroxisomal thiolase
(PTL) and CYP4A1 increased markedly in both PRIP
+/+
mice and in mice lacking hepatic PRIP, following
treatment with the PPARα ligand, Wy-14643. Also,
PPARα mRNA levels remained essentially similar in
control and Wy-14,643-treated mice [Sarkar et al., 2007].
Based on these results, this study concluded that NCoA6
is redundant in liver in activating PPARα- and
CAR-mediated gene expression, while PBP/TRAP220
was found to be essential for PPARα and CAR activation
[Sarkar et al., 2007].
Conclusions and future perspectives
Although NCoA6 was initially cloned as coactivator protein
for NRs, its detailed characterization by a number of
laboratories has uncovered its potential to enhance the
activity of a wide variety of other transcription factors
including c-Fos, c-Jun, CREB, NF-kB, ATF-2, heat shock
factors, E2F-1, SRF, and Rb, p53 and Sox9 [Goo et al.,
2004; Hong et al., 2004a; Hong et al., 2004b; Ko et al.,
2000; Kong et al., 2003; Lee et al., 1999; Lee et al., 2000;
Mahajan et al., 2007; Mahajan et al., 2002; Mahajan and
Samuels, 2000; Mahajan and Samuels, 2005].Thus, like
CBP/p300, NCoA6 may function as a transcriptional
co-integrator of NRs and other important transcription
factors involved in growth, proliferation, cytokine signaling,
metabolism, the immune response and apoptosis. Given
the wide spectrum of factors that are regulated by NCoA6,
an interplay of signaling pathways is expected to be
affected as a result of NCoA6 expression. It would be of
significant interest to determine if these factors associate
directly with NCoA6 or whether they interact with other
components of NCoA6 protein complexes. In this regard,
many of the factors described above have been shown
to interact with CBP/p300, suggesting that NCoA6 may
function to enhance the activity of such factors through
its interaction with CBP/p300, which occurs in vivo.
Although NCoA6 seems to be devoid of HAT activity, its
ability to associate with a large number of transcription
factors and signaling molecules strongly suggests that
NCoA6 plays a fundamental role in various coactivator
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with methyltransferases, and therefore, is involved in
modifying nucleosome architecture through histone
methylation. ALR/MLL2-knockdown affects cell
adhesion-related processes and suppresses cell growth
and migration capacity of cells [Issaeva et al., 2007].
Genes regulated by ALR include ECM-degrading enzyme,
heparanase, uPA/PL, BH-protocadherin, L1CAM, ALCAM
and Keratin17, consistent with decreased expression of
these molecules. ALR knockdown cells display reduced
growth kinetics, higher levels of intrinsic apoptosis and
impaired anchorage-independent growth in vitro [Issaeva
et al., 2007]. Interestingly, these ALR knockdown
phenotypes show similarities with the heterozygous
NCoA6(NRC) mice, which show defects in wound healing;
and growth retardation, slower cell proliferation and
enhanced apoptosis in NRC null embryos and null MEF
cells.
In addition to conformational alterations in NCoA6
mediated by liganded NRs, and possibly other
transcription factors, posttranslational modifications that
may regulate NCoA6 activity (e.g., phosphorylation of the
C-terminal STL inhibitory region) could play an important
role in modulating the intrinsic activity of NCoA6. Such
phosphorylation of NCoA6 by PKA and other kinases
may serve to communicate and integrate regulatory
events mediated by NRs or other transcription factors
and the signaling cascades generated by cell surface
receptors. NCoA6 has been shown to interact with a
number of factors in vitro and in vivo including CBP/p300,
DNA-PKc, DRIP130, NIF-1, CAPER, CoAA and PIMT.
In addition, NCoA6 is a component of ASCOM, ALR and
PTIP complexes.This raises the possibility that NCoA6
may be a component of distinct transcriptional regulatory
complexes, as has been found for the various “Mediator”
(DRIP/TRAP) complexes, which have somewhat different
protein compositions. In addition, a systematic analysis
of protein complexes of the yeast proteome indicates that
many proteins are shared by distinct protein complexes
which otherwise have very different compositions. Given
the complexity of the intermolecular network of NCoA6
and its multiple functions, it is also likely that NCoA6 is a
component of different regulatory complexes in the cell.
Unlike the p160/SRC family of coactivators, NCoA6 is a
single copy gene and has no apparent closely related
genes in the human genome. Since NCoA6 appears to
modulate the activity of many transcription factors, it is
not surprising that deletion of both NCoA6 alleles is
embryonic lethal.Thus, like CBP, p300 or TRAP220,
NCoA6 appears to be an essential gene involved in the
regulation of growth, development and cell survival.
Although full length NCoA6 has been studied in detail,
various sized mRNAs are expressed in different tissues,
which likely reflect alternative splicing of the NCoA6 gene.
Most of these isoforms, some of which are tissue-specific,
have not been well characterized. Depending on the
composition of the protein, such isoforms may mediate
specific effects or selectively interact with specific protein
complexes in the cell.Thus, some of the described
isoforms lack the C-terminal STL region which interacts
with CBP/p300, DRIP130 and DNA-PKc, while retaining
the interaction domain for NIF-1, PIMT and CoAA. In
addition, such an isoform would lack LxxLL-2, which
exhibits preference for the LXRs. Furthermore, an NCoA6
isoform lacking the inhibitory C-terminal STL region, but
which retains LxxLL-1 and AD2, might be expected to be
a more active isoform of NCoA6. AIB3 is a distinct isoform
of NCoA6 with a unique N-terminus. Studies on AIB3 may
reveal some interesting functional difference with NCoA6.
Thus, although NCoA6 is a single copy gene,
tissue-specific alternative splicing of the gene may
generate isoforms which may exhibit differences in
intrinsic activity, and/or lead to specific or restricted target
tissue response(s) compared with full length NCoA6.
In summary, NCoA6 (NRC/ASC-2/RAP250/TRBP/PRIP)
is an essential coregulator of NRs and other transcription
factors and exhibits pleiotropic effects on a wide variety
of processes [Mahajan and Samuels, 2005]. Recent
studies of NCoA6
+/- mice indicate that haploid expression
of NCoA6 leads to a variety of phenotypes, indicating that
NCoA6
+/- mice may prove useful in deciphering the role(s)
of NCoA6 in various processes in vivo.These studies,
and studies on the various NCoA6 isoforms and NCoA6
complexes, should lead to a more comprehensive
understanding of the contribution(s) of NCoA6 in
mediating effects of the NRs and other factors involved
in controlling growth, development, apoptosis, wound
healing, reproduction and metabolic regulation. Due to
embryonic lethality, the role of NCoA6 in various cell types
and in the adult mice has not been fully explored. It is
likely that NCoA6 is regulated in a cell and tissue
type-specific manner, thus potentially making NCoA6 a
very important molecule in the regulation of NR activities.
NCoA6 may emerge as a specific coactivator for a specific
set of NRs due to the fact that NCoA6 displays
NR-specific interaction through LxxLL-2. Already, some
data has accumulated regarding the role of NCoA6 in
vivo; however, future studies should be focused on
conditional knockouts of NCoA6 in various tissues to gain
insights into tissue-specific functions of NCoA6. NCoA6
may be involved in regulating fat metabolism and energy
homeostasis because of its interactions with PPARs,
LXRs and TRs. An interesting question relates to why
does NCoA6 associate itself with at least 3 different
known protein complexes, such as ASCOM, ALR and
PTIP? Thus, researchers interested in mechanism of
transcription should address the role of NCoA6 in
proteomics. Soon after p160 coactivators were
discovered, various groups followed the kinetics of their
appearance and disappearance. Some models proposed
ordered recruitment, while some argued for cyclical
recruitment. Studies on NCoA6 clearly reflect that it is not
a core molecule of one particular coactivator complex.
Instead, NCoA6 dynamically associates itself with at least
3 different coactivator complexes (ASCOM, ALR and
PTIP).Thus, these studies raise the possibility that
NCoA6, through its associations, and much like CBP,
may be a co-integrator regulating transcription and cell
signaling.The role of NCoA6 in cholesterol metabolism
and efflux should be of general interest to biologists.Thus,
NCoA6 opens possibilities for pharmacological
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healing, cardiovascular diseases, obesity and insulin
resistance.
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